Alps Advisors Inc
- SEC CIK
- 0001376113
- Latest filing
- Jul 29, 2026
NBIX holding history
Neurocrine Biosciences Inc in every 13F filed by Alps Advisors Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NBIX overviewAll 13F holders of NBIXFull Q2 2026 holdings
- Shares (Q1 2026)
- 0
- Sold out in Q1 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 8
- Since Q3 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2026 | 0 | $0 | 0.0% | −3,246−100.0% | Sold out | Holders |
| Q4 2025 | 3,246 | $460.4K | <0.1% | +36+1.1% | Added | Holders |
| Q3 2025 | 3,210 | $450.6K | <0.1% | +3,210 | New | Holders |
| Q1 2025 | 0 | $0 | 0.0% | −2,901−100.0% | Sold out | Holders |
| Q4 2024 | 2,901 | $396.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 2,901 | $334.3K | <0.1% | +410+16.5% | Added | Holders |
| Q2 2024 | 2,491 | $342.9K | <0.1% | −15−0.6% | Reduced | Holders |
| Q1 2024 | 2,506 | $345.6K | <0.1% | −409−14.0% | Reduced | Holders |
| Q4 2023 | 2,915 | $384.1K | <0.1% | −165−5.4% | Reduced | Holders |
| Q3 2023 | 3,080 | $346.5K | <0.1% | +3,080 | New | Holders |